Information required | Optional information |
---|---|
- confirmation of the diagnosis GIST, based on morphological and immunohistochemical findings | |
- indicate the type of analysed material (primary tumor, metastasis, local relapse) | - indicate date of surgery if appropriate |
- in case of a primary GIST indicate the individual risk classification according to consensus classification [27] | - according to [5] |
- report on molecular findings for every exon analysed; indicate mutations on DNA and protein level in a standardized description according to [30] | - indicate homo-/hemizygous mutations - indicate type of examination method (e.g. PCR and DNA sequencing) |
- report on expected response to imatinib treatment based on the individual mutation type, according to recent recommendations; - KIT exon 9: better response to 800 mg daily - KIT exon 11: best response (at 400 mg daily) - PDGFRA exon 18: according to special type of mutation (D842V resistant, deletions mostly responsive) | - report on prognostic relevance of the individual mutation type for clinical behaviour, according to recent data, e.g. [28] |
- give an individual suggestion for adjuvant therapy, based on the individual mutation type and according to recent consensus recommendations |